Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 8/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056217 | 0.81 | ALDH1A1 (0.42) | ABCB1TNFDPP4MEN1MAPT | |
| SCHEMBL6491480 | 0.81 | LMNA (0.51) | MAPTLMNAMAPK1 | |
| SCHEMBL7055139 | 0.80 | ALDH1A1 (0.41) | ABCB1TNFMEN1MAPTKMT2A | |
| SCHEMBL6499213 | 0.79 | HSD17B10 (0.44) | MEN1TP53MAPTKMT2ALMNA | |
| SCHEMBL6498960 | 0.77 | HSD17B10 (0.50) | ABCB1MAPTKMT2ARXFP1POLB | |
| SCHEMBL6489335 | 0.77 | HSD17B10 (0.46) | MEN1MAPTKMT2APDE3BPDE3A | |
| SCHEMBL7061647 | 0.75 | MAPK1 (0.37) | MEN1MAPTKMT2ALMNAMAPK1 | |
| SCHEMBL1807703 | 0.74 | ABCB1 (0.50) | ABCB1TNFDPP4MEN1TP53 | |
| SCHEMBL7058670 | 0.74 | MAPK1 (0.36) | DPP4MEN1MAPTKMT2ALMNA | |
| SCHEMBL7060393 | 0.72 | MAPK1 (0.39) | MEN1MAPTKMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908932-B2 | Cancer therapy | ICONIX PHARMACEUTICALS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | ENTELOS HOLDING CORP. | 2003-08-07 | — | — | US | disclosed |
| WO-2003035618-A2 | MODULATORS OF PHOSPHOINOSITIDE 3-KINASE | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149074-A1 | Modulators of phosphoinositide 3-kinase | PIK3R1, PIK3R3, PIK3R4 | ABCB1 2316/4885TNF 4873/4885DPP4 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.